32 research outputs found
Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer
Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received one prior platinum-based chemotherapy received 175 or 210 mg m−2 PPX or 75 mg m−2 docetaxel. The study enrolled 849 previously treated NSCLC patients with advanced disease. Median survival (6.9 months in both arms, hazard ratio=1.09, P=0.257), 1-year survival (PPX=25%, docetaxel=29%, P=0.134), and time to progression (PPX=2 months, docetaxel=2.6 months, P=0.075) were similar between treatment arms. Paclitaxel poliglumex was associated with significantly less grade 3 or 4 neutropenia (P<0.001) and febrile neutropenia (P=0.006). Grade 3 or 4 neuropathy (P<0.001) was more common in the PPX arm. Patients receiving PPX had less alopecia and did not receive routine premedications. More patients discontinued due to adverse events in the PPX arm compared to the docetaxel arm (34 vs 16%, P<0.001). Paclitaxel poliglumex and docetaxel produced similar survival results but had different toxicity profiles. Compared with docetaxel, PPX had less febrile neutropenia and less alopecia, shorter infusion times, and elimination of routine use of medications to prevent hypersensitivity reactions. Paclitaxel poliglumex at a dose of 210 mg m−2 resulted in increased neurotoxicity compared with docetaxel
Chemotherapy for malignant pleural mesothelioma: past results and recent developments
PubMedWo
Altered purine and pyrimidine metabolism in erythrocytes with purine nucleoside phosphorylase deficiency
Purine and pyrimidine metabolism was compared in erythrocytes from three patients from two families with purine nucleoside phosphorylase deficiency and T-cell immunodeficiency, one heterozygote subject for this enzyme deficiency, one patient with a complete deficiency of hypoxanthine-guanine phosphoribosyltransferase, and two normal subjects. The erythrocytes from the heterozygote subject were indistinguishable from the normal erythrocytes. The purine nucleoside phosphorylase deficient erythrocytes had a block in the conversion of inosine to hypoxanthine. The erythrocytes with 0.07% of normal purine nucleoside phosphorylase activity resembled erythrocytes with hypoxanthine-guanine phosphoribosyltransferase deficiency by having an elevated intracellular concentration of PP-ribose-P, increased synthesis of PP-ribose-P, and an elevated rate of carbon dioxide release from orotic acid during its conversion to UMP. Two hypotheses to account for the associated immunodeficiency—that the enzyme deficiency leads to a block of PP-ribose-P synthesis or inhibition of pyrimidine synthesis—could not be supported by observations in erythrocytes from both enzyme-deficient families.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44134/1/10528_2004_Article_BF00484238.pd
Phase II trial of ZD0473 as second-line therapy in mesothelioma
A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural mesothelioma has been completed. The objectives were to evaluate the activity and tolerability of ZD0473 in patients with relapsed or progressive disease who had received one prior chemotherapy regimen. Forty-seven patients were recruited onto the trial, all aged >18 years with a life-expectancy >12 weeks, and World Health Organization (WHO) performance status ≤2. A starting dose of 120 mg/m 2 was administered to 14 patients, six of whom subsequently had their dose escalated to 150 mg/m2. Thirty-three patients received a starting dose of 150 mg/m2. In total, 147 treatment cycles were administered (median number of cycles 3 [range 1-6]). The main toxicity of ZD0473 was haematological (thrombocytopenia) and the most common non-haematological adverse event was nausea. There was no clinically significant nephro-, neuro-, or oto-toxicity. Of the 43 patients evaluable for response, 12% had a minor response (defined by a reduction in lesion size ≥10% but <50%), 44% had stable disease, 40% had disease progression, and two patients died before an objective response could be assigned. Median time to progression and death in evaluable patients was 77 days (95% confidence interval [CI]: 44, 105 days) and 203 days (95% CI: 165, 277 days), respectively. In conclusion, although ZD0473 demonstrated a manageable tolerability profile, no complete or partial responses were seen in second-line treatment of mesothelioma. This trial also demonstrates that clinical trials in second-line mesothelioma patients are feasible. © 2002 Elsevier Science Ltd. All rights reserved.Articl
N6-Monobutyryladenosine 3' : 5'-Monophosphate as the Biologically Active Derivative of Dibutyryladenosine 3' : 5'-Monophosphate in HeLa S3 Cells
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)
Oral topotecan demonstrates clinical activity in relapsed non-small cell lung cancer. Results from an open-label, phase III study (387) comparing oral topotecan to intravenous docetaxel
Dissociations in the effects of beta2-adrenergic receptor agonists on cAMP formation and superoxide production in human neutrophils: Support for the concept of functional selectivity
In neutrophils, activation of the beta2-adrenergic receptor (beta2AR), a Gs-coupled receptor,
inhibits inflammatory responses, which could be therapeutically exploited. The aim of this study was to
evaluate the effects of various beta2AR ligands on adenosine-3',5'-cyclic monophosphate (cAMP)
accumulation and N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP)-induced superoxide anion
(O2*-) production in human neutrophils and to probe the concept of ligand-specific receptor
conformations (also referred to as functional selectivity or biased signaling) in a native cell system.
cAMP concentration was determined by HPLC/tandem mass spectrometry, and O2*- formation was
assessed by superoxide dismutase-inhibitable reduction of ferricytochrome c. beta2AR agonists were
generally more potent in inhibiting fMLP-induced O2*- production than in stimulating cAMP
accumulation. (-)-Ephedrine and dichloroisoproterenol were devoid of any agonistic activity in the
cAMP assay, but partially inhibited fMLP-induced O2*- production. Moreover, (-)-adrenaline was equiefficacious
in both assays whereas the efficacy of salbutamol was more than two-fold higher in the O2*-
assay. In contrast to the agonists, the effects of beta2AR antagonists were comparable between the two
parameters on neutrophils. Differences between the data from neutrophils and recombinant test
systems were observed for the beta2AR agonists as well as for the beta2AR antagonists. Lastly, we
obtained no evidence for an involvement of protein kinase A in the inhibition of fMLP-induced O2*-
production after beta2AR-stimulation, although, in principle, cAMP-increasing substances can inhibit
O2*- production. Taken together, our data corroborate the concept of ligand-specific receptor
conformations with unique signaling capabilities and suggest that the beta2AR inhibits O2*-
production in a cAMP-independent manner